Compare NSP & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSP | AMLX |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1996 | 2021 |
| Metric | NSP | AMLX |
|---|---|---|
| Price | $53.46 | $34.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $47.67 | $21.56 |
| AVG Volume (30 Days) | 446.5K | ★ 3.5M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.45% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $6,812,000,000.00 | $380,786,000.00 |
| Revenue This Year | $3.45 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $53.41 | ★ N/A |
| Revenue Growth | 3.51 | ★ 1612.94 |
| 52 Week Low | $18.57 | $9.15 |
| 52 Week High | $57.22 | $41.14 |
| Indicator | NSP | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 59.58 | 71.92 |
| Support Level | $47.54 | $12.54 |
| Resistance Level | $55.09 | $41.14 |
| Average True Range (ATR) | 2.35 | 2.27 |
| MACD | -0.24 | 0.63 |
| Stochastic Oscillator | 88.80 | 75.83 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.